- Home
- BLIV vs BOLD Comparison
BLIV vs BOLD Comparison
Compare BLIV & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLIV
- BOLD
- Stock Information
- Founded
- BLIV 2014
- BOLD 2018
- Country
- BLIV Singapore
- BOLD United States
- Employees
- BLIV N/A
- BOLD N/A
- Industry
- BLIV
- BOLD
- Sector
- BLIV
- BOLD
- Exchange
- BLIV NYSE
- BOLD Nasdaq
- Market Cap
- BLIV 29.0M
- BOLD 24.4M
- IPO Year
- BLIV 2025
- BOLD 2024
- Fundamental
- Price
- BLIV $2.35
- BOLD $1.16
- Analyst Decision
- BLIV
- BOLD Buy
- Analyst Count
- BLIV 0
- BOLD 3
- Target Price
- BLIV N/A
- BOLD $4.00
- AVG Volume (30 Days)
- BLIV 40.4K
- BOLD 107.3K
- Earning Date
- BLIV 01-01-0001
- BOLD 08-15-2025
- Dividend Yield
- BLIV N/A
- BOLD N/A
- EPS Growth
- BLIV N/A
- BOLD N/A
- EPS
- BLIV N/A
- BOLD N/A
- Revenue
- BLIV $1,355,200.00
- BOLD N/A
- Revenue This Year
- BLIV N/A
- BOLD N/A
- Revenue Next Year
- BLIV N/A
- BOLD N/A
- P/E Ratio
- BLIV N/A
- BOLD N/A
- Revenue Growth
- BLIV N/A
- BOLD N/A
- 52 Week Low
- BLIV $1.85
- BOLD $1.00
- 52 Week High
- BLIV $6.40
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- BLIV N/A
- BOLD N/A
- Support Level
- BLIV N/A
- BOLD N/A
- Resistance Level
- BLIV N/A
- BOLD N/A
- Average True Range (ATR)
- BLIV 0.00
- BOLD 0.00
- MACD
- BLIV 0.00
- BOLD 0.00
- Stochastic Oscillator
- BLIV 0.00
- BOLD 0.00
About BLIV BELIVE HOLDINGS
BeLive Holdings is a holding company. The company is a technology solution provider for live commerce and shoppable short videos. The company enables its customers in interactive and immersive live and video commerce to the online businesses, and enables customers to create videos for more traffic and good shopping experiences on their platforms. The company generates revenue from the provision of BeLive White-Label Solutions and BeLive SaaS Solutions.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.